ELIEZER PORTNOY: Open Payments
NPI 1891140083 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,309 in 72 payments from 24 companies in 2025. Trend: 2023 $344 · 2024 $755 · 2025 $1,309
Food & beverage: $1,210Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 10 | $222 |
| E.R. Squibb & Sons, L.L.C. | 10 | $161 |
| AstraZeneca Pharmaceuticals LP | 10 | $160 |
| Novartis Pharmaceuticals Corporation | 6 | $100 |
| Celgene Corporation | 5 | $85 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| PFIZER INC. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $42 |
| TAIHO ONCOLOGY, INC. | 2 | $42 |
Products named: OPDIVO, RYBREVANT, LYNPARZA, REBLOZYL, Enhertu, KISQALI, Nubeqa, ERLEADA.
Industry payments across NY — which companies pay providers there.
